Abstract:Imatinib mesylate (Gleevec or STI-571), a tyrosine kinase inhibitor, can potently block both platelet-derived growth factor (PDGF) receptor-α and β by inhibiting the receptor tyrosine kinase activity. Imatinib mesylate has been successfully used to treat patients with chronic myeloid leukemia (CML) and Ph positive acute lymphoid leukemia (ALL). However, a significant number of patients with imatinib mesylate treatment have developed neutropenia, thrombocytopenia and anemia (van Deventer, Hall et al. 2002). Our previous studies have demonstrated that PDGF/PDGFR plays an important role on thrombopoiesis, and blockage of PDGFR by imatinib inhibited the downstream signal pathway, which led to reduce of megakaryocyte production (Ye, et al. Haematologica, 2010). This may partially explain the imatinib-related thrombocytopenia. However, the role of imatinib on normal hematopoiesis remains to be investigated. In the present study, we identified the expression of PDGFR-β on the human megakaryoblastic cells: Meg-01, CHRF-288-11, Dami and M-07e, human erythromyeloblastoid leukemia cells: K-562 and human myeloblastic cells: HL-60 by RT-PCR, western blot and flow cytometry. We then demonstrated the effect of imatinib on normal hematopoiesis in the 8 wk old C57BL/6 mice model. Gleevec (25 mg/kg/day) dissolved in distilled water or water only were given orally for up to 2 wks. 15ul whole blood was taken from postorbital weekly to perform blood cell counts. The Gleevec -treated group showed a reduction of platelet count as compared to the control at day 14 (543.3±71.95×109/L vs. 330.0±62.23×109/L, n=5, P<0.05). Similarly, Gleevec caused a significant decrease in the number of white blood cells on day 14 (9.667×±0.8511×109/L vs. 6.080±0.8015×109/L, n=5, P<0.05). While no significant differences were found on red blood cell count between Gleevec and control groups. The mice bone marrow was harvested from each group to perform CFU assays. Gleevec significantly inhibited the formation of bone marrow CFU-MK (15.33±1.764 vs 3.333±0.6667, n=3), and CFU-GM(13.50±2.784 vs 6.333±0.7265, n=3) compared with the control. There were no significant differences found in CFU-GEMM and CFU/BFU-E formation between the Gleevec and control treatment. Our studies suggested that PDGFR were expressed on hematopoietic cells. Imatinib mesylate, an inhibitor of PDGFR, not only played an important role in malignant hematopoiesis, but also in normal hematopoiesis. Administration of Gleevec reduced white blood cells and megakaryocytes/platelets production, which implied its potential therapeutic role in treating myeloproliferative diseases, such as Essential Thrombocytosis.

Inhibitory Effects of Imatinib Mesylate on Human Epidermal Melanocytes.

Tyrosine Kinase Inhibitor Imatinib Mesylate Induces Generalized Skin Hypopigmentation in Chinese Patients with Chronic Myelogenous Leukemia.

Berbamine Exhibits Potent Antitumor Effects on Imatinib-Resistant CML Cells in Vitro and in Vivo

Effects of EGFR-TKI on epidermal melanin unit integrity: Therapeutic implications for hypopigmented skin disorders

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence from a Retrospective Study

Imatinib Targeting of KIT-Mutant Oncoprotein in Melanoma

Inhibition of IGF-IR Tyrosine Kinase Induces Apoptosis and Cell Cycle Arrest in Imatinib-Resistant Chronic Myeloid Leukaemia Cells.

Inhibitory Effect of 4-Chlorobenzoyl Berbamine on Imatinib-Resistant K562 Cells in Vitro and in Vivo

Stem Cell Factor-Inducible MITF-M Expression in Therapeutics for Acquired Skin Hyperpigmentation

C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells

Interruption of p38 MAPK -MSK1-CREB-MITF-M pathway to prevent hyperpigmentation in the skin

P19ink4d Inhibits Proliferation and Enhances Imatinib Efficacy Through BCR-ABL Signaling Pathway in Chronic Myeloid Leukemia.

Efficacy and safety of Imatinib in the 78 patients with advanced melanoma harboring KIT mutation

Imatinib Mesylate Has an Inhibitory Effect on Hematopoiesis in A Mice Model

[Effect of Tyrosine Kinase Inhibitor Imatinib Mesylate on Proliferation, Differentiation and Apoptosis of Kasumi-1 Leukemia Cell Line].

[Molecular Mechanism of Imatinib-Induced Thrombocytopenia in Treatment of Patients with CML].

A Polymethoxyflavone from Laggera Pterodonta Induces Apoptosis in Imatinib-Resistant K562R Cells Via Activation of the Intrinsic Apoptosis Pathway

Imatinib inhibits oral squamous cell carcinoma by suppressing the PI3K/AKT/mTOR signaling pathway

[Effect of ZD6474 on the Proliferation of Imatinib-Resistant K562 Cells].